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Combining genetic and clinical data into an informative risk prediction profile has
been an important ambition of personalized medicine. Single-nucleotide polymor-
phisms are commonly found throughout the genome and account for the majority of
interindividual genetic variation. To date, genome-wide association studies have led
to the discovery of thousands of disease-associated loci, including across dozens of
ophthalmic diseases and traits. However, compared with the clinical utility of identify-
ing rare Mendelian variants, the translation of these results to clinical practice has so far
been limited because such variants are found commonly in the population, and individ-
ually account for a very small risk. Recently, combining large numbers of these genetic
variants into polygenic risk scores (PRS) has shown clinically meaningful risk predic-
tion across several common diseases. PRS have the potential to translate the discov-
ery of common risk variants into individualized disease risk prediction, prognostication,
and may enable targeted treatments. In this context, we review the clinical utility of
PRS in three common, genetically complex ophthalmic conditions: primary open angle
glaucoma, age-related macular degeneration, and myopia.
Translational Relevance: Common genetic variants can be used to effectively stratify
the risk of disease development and progression and may be used to guide screening,
triaging, monitoring, or treatment thresholds.
Introduction
The rapid development of genomics in recent
years has substantially accelerated our understand-
ing of the genetic architecture of many complex
diseases. The increased affordability and throughput of
genomic assays, development of better tools to process
genomic data, and the availability of increasingly large
public datasets has allowed an unprecedented explo-
ration of human genomic variation. Over the past
decade, genome-wide association studies (GWAS) have
been extensively used to find associations between a
disease or trait and genetic loci, represented by single-
nucleotide polymorphisms (SNPs). SNPs are varia-
tions in a single DNA building block (nucleotide)
in the gene. A few million SNPs are found in each
person’s unique genetic sequence, bearing in mind
that the majority are not thought to be associated
with any disease.1 Only relatively common SNPs—
with allele frequency of at least 1%—are statisti-
cally confidently discovered to be associated with a
trait in GWAS, although increasing sample sizes and
newer analytical approaches are continuously improv-
ing the ability to detect robust associations with rarer
variants.
A better understanding of an individual’s risk of
disease, the severity of disease in those who develop
it, and their response to therapy are cornerstones
of personalized medicine—the notion that screening,
management, and interventions can be tailored specif-
ically to an individual, or at least stratified across
groups of similar individuals. This review will focus on
the polygenic risk model of diseases, and its applica-
tion in ophthalmology with a focus on primary angle
glaucoma (POAG), age-related macular degeneration
(AMD), and myopia, the leading causes of blindness
worldwide.2
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Polygenic Model of Complex Diseases
Monogenic or Mendelian diseases are primarily
driven by alterations in a single gene. These genetic
variants are typically rare but have a high effect size and
penetrance, meaning that they generally confer a high
risk of developing the associated disease. For example,
rare pathogenic variants in the OPTN (optineurin)
gene and copy number variants of the TBK1 (Tank-
binding kinase 1) gene lead to familial normal tension
glaucoma with highly penetrant autosomal dominant
inheritance.3,4 Similarly, most retinal dystrophies arise
from Mendelian variants and over 330 such retinal
dystrophy genes have been identified, such asmutations
in RHO (rhodopsin) leading to retinitis pigmentosa.5
In contrast, complex diseases have a polygenic
genetic architecture, which may involve hundreds
or thousands of contributing genes.6 In these
common complex diseases, each genetic variant
has a relatively small effect and does not lead to
the disease by itself. Therefore the discovery of
these disease-associated genomic variants requires
studies of large cohorts, especially for common
variants with very small effect sizes. This is commonly
the result of GWAS in which millions of genetic
variants are studied across many thousands of
individuals for association to a disease or trait. It
is important to note that individual SNPs discov-
ered by GWAS are relatively common in the normal
population, often with a minor allele frequency above
1%. That is, these variants are present in at least 1%
of the normal population if heterozygous, or slightly
lower proportions accounting for homozygous people;
thus the study of disease association of these variants
requires a large and ideally well-phenotyped cohort.
Disease association for rarer variants requires a differ-
ent approach such as linkage mapping or whole-exome
sequencing of families with the same rare disease.
Many common adult-onset diseases have polygenic
and environmental contributions, including POAG,
AMD, type 2 diabetes, dyslipidemia, and coronary
artery disease.6–10 For example, although there is a
strong genetic contribution to AMD risk, smoking has
been well established as a key modifiable environmen-
tal risk factor for the development and progression of
AMD.11,12
Although each SNP explains only a small propor-
tion of genetic risk and heritability, the additive effects
of tens or hundreds, up to hundreds of thousands
in some studies, of SNPs amount to a risk equiv-
alent to a single monogenic variant.13 Furthermore,
common variants of very small effect sizes are diffi-
cult to isolate statistically from noise in GWAS, yet
they still contribute to disease risk and account at least
partially for the missing heritability unexplained by
the currently discovered variants.14 As larger studies
discover additional loci,8,9,15 it is evident that SNPs
with small effect sizes conjointly play a significant role
in genetic risk.16 The complex interplay of these genetic
networks and the effect of one locus onmultiple pheno-
types (termed pleiotropy), likely owing to their involve-
ment in a shared biological pathway, as well as environ-
mental influences are important in the development of
complex traits.16,17
Development of Polygenic Risk Scores
A polygenic risk score (PRS)—also known as
a genetic risk score—is a quantitative probabilistic
summary of an individual’s genetic susceptibility to a
disease or trait (Fig.). In its simplest form, it is a sum
of the number of risk alleles carried by an individ-
ual.18 More commonly, the variants are weighted by
their magnitude of effect on the disease or trait—the
estimated regression coefficient of the variant—based
on the summary statistics of the GWAS.18 This allows
the risk score to reflect the effect size of the variants in
addition to their total numbers, and therefore is a more
accurate risk predictor.
Disease-associated SNPs included in a PRS are
discovered via GWAS, in which several million SNPs
are statistically compared with a disease (case–control
setting) or phenotype. To minimize false discovery
from multiple testing, a stringent genome-wide P value
threshold of 5 × 10−8 is used in discovery studies, and
P value adjustmentmethods such as Bonferroni correc-
tion are used for validation studies. However, SNPs
with borderline significance not meeting the genome-
wide threshold may still be associated with disease,16,19
thus a PRS may improve the estimate of the “true”
genetic risk and predictive power by including a larger
number of SNPs using more lenient statistical thresh-
olds.18 To account for correlated and coinherited SNPs
(said to be in high linkage disequilibrium [LD]), SNPs
that are in high LD to others are usually excluded
via P value thresholding; alternatively, LD is modeled
into the PRS mathematically using methods such as
LDpred or lassosum.20,21
When applied in a clinical context, the raw number
of an individual’s PRS (e.g., 12.395) is not intuitive to
interpret, and so is better presented as their percentile
risk relative to the normal population or study cohort
(e.g., 90th percentile). For instance, a person in the 90th
percentile of a weighted PRS carries disease-associated
alleles whose combined effect sizes—i.e., the genetic
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Figure. Development and clinical utility of a PRS for a sample disease.
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burden—exceeds that of 90% of the normal popula-
tion or study cohort. A commonly used PRS stratifi-
cation method is quintiles, in which the bottom 20%
is considered low risk, the top 20% as high risk, and
the rest as intermediate risk.9,13,22,23 Similarly, tertile or
decile groups may be used. Importantly, a PRS allows
disease risk stratification but is never a diagnostic tool:
its clinical utility is best achieved when combined with
demographic and/or clinical factors usually evaluated
in routine clinical risk assessment.
Authors sometimes seek to quantify the utility of a
PRSusing the area under the receiver operating charac-
teristic curve (AUC). AUC is a summary statistic that
indicates the discriminatory powers of a test to differ-
entiate a binary outcome or set of categories. Mathe-
matically, it is calculated as the area under the curve
fitted to all the test sensitivities for each corresponding
specificity (often one minus specificity). It can be used
to set an optimal test threshold for maximized sensi-
tivity or specificity. Although commonly reported in
the PRS literature, the AUC has been justifiably criti-
cized because of its lack of clinical interpretation—it is
a metric of test performance in the study cohort and
does not inform the individual about their risk, nor
does it quantify the magnitude of risk.24 Furthermore,
from a clinical point of view, PRS is best suited as a
genetic disease risk probability index (e.g., on a contin-
uous spectrum of risk) as opposed to the dichotomous
end-point approach commonly used in AUC calcula-
tions. In the case of age-related diseases such as POAG
and AMD, a limitation of any dichotomous end-point
study is the uncertain likelihood of younger individ-
uals developing the disease in question later in life,
which can be mitigated to some extent by prespec-
ified age thresholds. Instead, the utility of the PRS
can be reported by how informative it is in identify-
ing high-risk individuals compared with low-risk or
average-risk individuals. This can be done by reporting
the odds ratio (OR) of developing the disease between
the genetic risk groups and in reference to the general
population risk, or additionally, by reporting the PRS
association to a disease-specific metric, such as the age
of diagnosis, or other measures of severity.
Clinical Utility of the PRS in
Ophthalmology
The clinical utility of PRS relies on its ability
to effectively identify individuals who would benefit
from modified screening approaches for disease detec-
tion (frequency or age threshold for screening tailored
to risk group) or interventions for disease manage-
ment or progression (e.g., prioritization of thera-
peutic interventions, and management of risk and
benefits of interventions). In nonophthalmic diseases,
the clinical utility of PRS has been mainly reported in
cardiovascular diseases, diabetes, inflammatory bowel
diseases, cancers, and psychiatric conditions.13,25–29
For instance, disease risk stratification by PRS is effec-
tively able to identify individuals at the highest risk
of developing coronary artery disease, stroke, atrial
fibrillation, and type 2 diabetes.13,28 This allows early
intervention with lifestyle modification or medications,
which has been shown to attenuate disease risk in high-
risk individuals.28,30,31 For example, statin therapy has
a greater absolute risk reduction of primary coronary
heart events in high-risk PRS individuals than inter-
mediate or low-risk groups.22 Furthermore, screen-
ing programs, particularly for breast, prostate, and
colorectal cancers, can be effectively personalized to
the individualized risk based on PRS and demographic
stratification.26,32 An overview of personalized clini-
cal utility of PRS has been reviewed elsewhere.33 We
will review the potential clinical utility of PRS in three
common, genetically complex ophthalmic conditions:
POAG, AMD, and myopia.
Primary Open Angle Glaucoma
Glaucoma is the leading cause of irreversible blind-
ness worldwide affecting over 64 million people and
expected to increase in prevalence with the aging
population.34 Primary open angle glaucoma is themost
common subtype, in which the iridocorneal angle is
open and there is no secondary cause of elevated
intraocular pressure (IOP). It is one of the most herita-
ble of all common diseases,35 and first-degree relatives
of individuals with POAGare at 9.2-fold higher relative
risk of developing glaucoma.36 The study of the genetic
architecture of POAG has been complemented by
genetic association studies of related ocular traits
associated with POAG — termed endophenotypes —
namely IOP and optic disc nerve head morphology
such as the vertical cup-to-disc ratio (VCDR).37 POAG
and its endophenotypes are highly heritable with recent
association studies reporting over 100 loci associated
with IOP, over 50 with VCDR, and over 100 correlated
with POAG.15,38,39
The high heritability of POAG and its correlated
endophenotypes, in addition to the effectiveness of
early intervention (e.g., topical medications, laser, or
incisional surgery) to prevent otherwise irreversible
vision loss, has made POAG a focus of PRS stratifi-
cation. The earliest studies have demonstrated signifi-
cant but modest discriminatory powers for a glaucoma
PRS.40–42 In 2015, Tham et al.41 developed a glaucoma
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PRS combining seven IOP-associated and 18 VCDR-
associated SNPs known at the time, and reported a
modestly higher odds of developing POAG in the top
tertile of the PRS relative to the bottom tertile in
a multiethnic cohort from Singapore (IOP-PRS OR,
2.50; 95% confidence interval [CI], 1.54–4.02; VCDR-
PRS OR, 2.31 [95% CI, 1.50–3.55]). Mabuchi et al.40
conducted an unweighted PRS utilizing nine IOP-
associated SNPs in a Japanese cohort and reported
a modest association with higher tension POAG (OR
per risk allele = 1.12; 95% CI, 1.01–1.24). These early
studies were limited by including only a small number
of SNPs in the PRS and applying it to relatively small
POAG cohorts. Mabuchi et al.40 also did not weight
the loci effect size—an approach now superseded by
weighted PRS.18
Backed up by larger GWAS, recent glaucoma PRS
studies have utilized an increasingly larger number
of variants associated with POAG and its endophe-
notypes. MacGregor et al.15 generated a PRS using
101 IOP-associated SNPs and two previously reported
VCDR-associated SNPs, and showed that the top
PRS decile of an independent Australian case–control
glaucoma cohort had a significantly higher risk of
POAG relative to the bottom decile (OR, 5.6 [95% CI,
4.1 – 7.6]). This magnitude of risk was previously only
reported for rarer monogenic variants.43 Gao et al.44
constructed an inclusive PRS using 1691 SNPs associ-
ated with IOP using a more lenient statistical thresh-
old (P < 5 × 10−5) and reported a six-fold higher
POAG risk in the top quintile relative to the bottom
quintile of an internal validation dataset (OR, 6.34
[95% CI, 4.82–8.33]). This improved risk prediction
can be attributed to a more inclusive SNP selection
in the PRS; however, a limitation of this approach
was that the test cohort and the GWAS discovery
cohort were both from the UKBiobank and thus share
geographic, temporal, and methodological properties.
We recently reported a PRS derived from 146 IOP-
associated SNPs to be associated with higher maximal
IOP, younger age of glaucoma diagnosis, more family
members affected, and higher treatment intensity in
an independent Australian cohort.23 These findings
were also validated in an independent cohort of early
glaucoma cases, further supporting the utility of IOP-
derived variants in glaucoma risk stratification.23
Another PRS constructed from 68 VCDR-
associated SNPs applied to a Latino population
showed a relatively modest risk of POAG (OR, 1.75
[95% CI, 1.09–2.81] for the top quintile relative to the
bottom quintile).45 This is likely owing to input SNPs
being derived from GWAS of primarily European and
Asian ancestries, which are unlikely to capture all risk
variants relevant to the Latino population. Addition-
ally, VCDR variants alone have a lower discriminatory
power in identifying POAG and highlights the impor-
tance of utilizing multiple glaucoma endophenotypes
at a more inclusive statistical threshold. Most recently
our group reported a comprehensive POAG PRS
utilizing multiple correlated traits (glaucoma diagno-
sis, IOP, and optic disc diameter adjusted VCDR)
inclusive of 2673 uncorrelated SNPs. In an indepen-
dent case–control POAG cohort, individuals in the top
decile of the PRS distribution had 14.9-fold higher
risk (95% CI, 10.7–20.9) of glaucoma relative to the
bottom decile, along with an even greater risk in high-
tension glaucoma cases only (top decile vs. bottom
decile of the PRS OR, 21.5, 95% CI, 12.5–37.0).38
The addition of PRS significantly improved glaucoma
risk prediction compared with a model with age and
sex alone, which supports the added utility of PRS
compared with demographic risk factors in risk strat-
ification (AUC 0.76, 95% CI, 0.72–0.81 vs. 0.71, 95%
CI, 0.67–0.76; P = 2.8 × 10−4).38
The transferability of glaucoma PRS—which are
currently primarily derived from European ances-
try individuals—have been studied in South Asian
and African cohorts. Our aforementioned European
ancestry–derived multitrait glaucoma PRS was predic-
tive of glaucoma in the South Asian Ancestry individ-
uals of the UK Biobank (AUC = 0.76 in a model
with age and sex, 95% CI, 0.73–0.79).38 PRS based
on glaucoma-associated loci discovered in European
or Asian cohorts have shown to have transferability in
risk predicting glaucoma risk in African cohorts.46–48
Bonnemaijer et al.47 reported that a weighted PRS
inclusive of 15 glaucoma-associated SNPs was associ-
ated with POAG in an African ancestry cohort (OR
1.59, 95%CI, 1.26–1.93), whereby the top PRS quintile
had a two-fold increase in POAG risk relative to the
bottom PRS quintile. Interestingly, despite the predic-
tive ability of the weighted PRS, none of these loci were
individually associated with POAG in this cohort.47
This is in keeping with the GWAS results reported
by Hauser et al.,49 whereby the majority of POAG
risk loci previously identified in European cohorts
had a significantly smaller effect sizes and statisti-
cal significance in African ancestry individuals. Thus
the predictive ability of the PRS would improve by
identifying ancestry-specific variants (which may be
not be the same variants identified in European ances-
try only GWAS due to transethnic LD patterns) and
improving fine mapping to identify causal variants.48
It is encouraging that the current PRS show some
evidence of transethnic transferability despite the
limitations of ethnic diversity in the discovery cohorts
and the variability in effect sizes of risk loci between
ancestries.49
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The natural history of POAG and the benefits of
early intervention make glaucoma a compelling disease
for further clinical trials of PRS testing. Our study
demonstrated that the glaucoma PRS was associated
with a younger age of glaucoma diagnosis with individ-
uals in the top decile being diagnosed on average
7 years earlier than the bottom decile group.38 This is
in keeping with the results from another POAG PRS
study that utilized 12 POAG-associated SNPs report-
ing younger age of POAG diagnosis (5 years younger
on average in the top 5% of the PRS relative to the
bottom 5%).50 Another study showed a similar trend
in the age of diagnosis in a Japanese POAG cohort,
using a PRS inclusive of 17 IOP-related variants.51
Furthermore, our findings showed structural progres-
sion of early glaucoma and likelihood for incisional
surgery in individuals with advanced glaucoma and
high PRS, even after adjustment for known risk factors
of progression of age and IOP.38 We also reported
that individuals with a high IOP-associated PRS had
a higher early-morning and outside office hours IOP
even after adjustment for a clinically measured IOP,
whereby individuals in the highest quintile of the PRS
were 5.4-fold more likely (95% CI, of OR 1.3–23.6) to
have early-morning IOP spikes relative to the lowest
quintile.52 Interestingly, this association was stronger
using a PRS exclusive to IOP-associated variants than
a more comprehensive glaucoma PRS, suggesting an
added benefit of trait-specific PRS in predicting pheno-
typic variations of a disease.52 Ultimately, a compre-
hensive and validated glaucoma PRS may be used to
personalize glaucoma monitoring and management in
high-risk compared with average- or low-risk individu-
als.
Currently, genetic testing can be done in early-
onset glaucoma cases to identify individuals and their
relatives at a higher risk of glaucoma.53 Individuals
carrying variants in genes known to cause early-onset
glaucoma such as MYOC would benefit from genetic
counseling and a personalized approach to screen-
ing and management. Further, common variants may
influence the penetrance of incompletely penetrant
“monogenic” variants. Our aforementioned PRS effec-
tively stratifies cumulative glaucoma risk in MYOC
p.Gln368Ter carriers, the most common disease-
causing variant for POAG, with individuals in the
highest tertile of the PRS having six-fold increase in
absolute risk of glaucoma by age 60 years relative to
the lowest tertile.38
The latest glaucoma PRS risk stratification is
promising in identifying individuals not carrying single
high-impact variants to be at a higher risk of develop-
ing advanced glaucoma and disease progression.23,38 A
PRS-based risk stratification will be more effective in
combination with demographic risk factors and may
be best applied to older individuals (50 years or older),
those with a family history of glaucoma, or those who
may have optic disc features suspicious of developing
glaucoma.54 In addition, PRSmay aid in triaging refer-
rals of “glaucoma suspects” to specialists by identifying
high-risk individuals prior to clinical review, resource
allocations in light of increasing glaucoma prevalence,
and potentially a targeted screening program.54
Age-Related Macular Degeneration
AMD is known to be a highly heritable disease, and
a recent large GWAS has discovered genetic variations
distributed over 34 loci accounting for over half of
the disease heritability.8 Although AMD is a complex
disease with several common and rare genetic variants
associated with the disease, variants in the genes
ARMS2/HTRA1 and CFH account for a much larger
risk than other genes.8 The AMD-associated variants
in these genes are common in individuals of European
ancestry (minor allele frequency of 20%–40%), and
each account for a two- to three-fold increased risk of
AMD.8,55
The discovery of relatively large-effect size genetic
variants for AMDhas led to a great interest in develop-
ingmodels of disease prediction, including those incor-
porating environmental and ocular risk factors.8,55–57
For instance, a model with 26 AMD-associated SNPs
alongside age and sex was highly predictive of late
AMD (AUC, 0.82; 95% CI, 0.79–0.86), outperform-
ing nongenetic risk models (AUC, 0.78; 95% CI, 0.74–
0.82).58 After the discovery of additional AMD risk
variants using a GWAS of 16,144 AMD patients,
Fritsche et al.8 reported an AMD PRS including
52 AMD-associated SNPs (of which seven were rare
variants with minor allele frequency <1%), in which
individuals in the highest decile had a 44-fold higher
risk of developing advanced AMD relative to the
lowest decile. Of note, thismagnitude of risk is likely an
overestimate as the test dataset was a modeled general
population derived from the discovery case–control
dataset.
Several studies have used PRS and known ocular
and environmental risk factors to stratify AMD
progression risk: the majority focusing on variants
strongly associated with AMD such as those in CFH
and ARMS2.59–63 For instance, the presence of two
or more risk alleles in CFH and/or ARMS2 was
associated with progression of AMD during a 10-
year follow-up (OR, 2.03; 95% CI, 1.46–2.81), which
appeared to be synergistic with known environmen-
tal risk factors.60 More broadly, a recent machine
learning–derived model inclusive of PRS, age, diet,
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smoking, education, and ocular measurements was
found to be highly predictive of incident advanced
AMDat 5, 10, and 15 years follow-up (AUC, 0.92; 95%
CI, 0.90–0.95 at 10 years).64
As observed in POAG and many other conditions,
the inclusion of additional AMD risk variants in a
PRS improves its predictive performance. Ding et al.57
used a PRS comprising 34 AMD-associated SNPs to
stratify the risk of progression to late AMD over up
to 10.3 (SD 1.7) years. There were markedly increased
rates of progression to late AMD in individuals at
the highest quartile of the PRS (50% progression)
compared with the lowest quartile (6.9% progression)
and the intermediate group (22% progression), which
was further replicated in an independent cohort.57
Similarly, an AMD PRS predicted second-eye involve-
ment in unilateral AMD cases in a Japanese cohort
(51% 10-year hazard rate in the top decile vs. 2.3%
in the lowest decile).65 Another PRS comprising all
52 AMD-associated variants was applied to an
independent prospective German cohort of AMD
patients, and was associated with drusen load in agree-
ment with earlier reports from the AREDS cohort.66,67
Moreover, the 52-variant PRS was associated with
drusen progression in individuals with low drusen load
at baseline, and both drusen and AMD progression
to late disease in those with intermediate drusen load
during the mean 6.5 years of follow-up.66
Seddon and Rosner68 have incorporated 13 AMD-
associated risk loci into a predictive model including
known demographic and ocular risk factors (baseline
AMD grading) in the AREDS cohort and further
validated this in an independent longitudinal AMD
cohort. This risk model was predictive of AMD
progression to advanced disease (AUC, 0.90 over
12 years), geographic atrophy (AUC, 0.87), and neovas-
cular disease (AUC, 0.86). Of note, both common
and rare genetic variants were included in the model;
these variants are only a subset of the known AMD-
associated risk loci because the authors used a stepwise
regression approach with P value thresholds as the
inclusion criteria for genetic variants.68 This approach
is useful for optimizing variable selection in the model
but excludes small effect-size variants, which may
additively infer additional risk. The authors further
investigated the added utility of PRS in a nongenetic
risk model using the Net Reclassification Improve-
ment method, in which predicted risk stratification
at baseline is compared with progression outcome
between two models. The model incorporating PRS
improved the classification of eyes that ultimately
progressed to AMD, with progressing eyes more likely
to be classified as high risk, and nonprogressing eyes
as low risk, when genetic factors were considered. For
instance, 63%of eyes that progressedwhile being classi-
fied as “medium risk of progression” (10%–30% risk
over 10 years) in a nongenetic model, were more appro-
priately identified as “high or very high risk of progres-
sion” by the addition of genetic loci to the model.68
This highlights the improved risk stratification and
added clinical utility of an AMD PRS compared with
known demographic and ocular risk factors.
In summary, an AMD PRS incorporating all
possible loci vastly improves on existing clinical risk
stratification for both disease onset and progression.
However, aside from antioxidant and mineral supple-
mentation, there are no effective early therapies in
dry AMD.69 Despite this, AMD risk factor modifi-
cation such as smoke cessation and weight loss may
be valuable interventions in high-risk individuals. This
has previously led the American Academy of Ophthal-
mology to recommend against routine genetic screen-
ing for complex diseases such as AMD.70 Of note, this
recommendation was published in 2012 and does not
consider the evolving evidence for using the PRS in risk
prediction.
Myopia
The etiology of myopia is complex, with both
environmental and genetic factors, as well as the
interaction between them, contributing to the clini-
cal presentation of myopia and its progression.71 Our
understanding of common genetic variants associ-
ated with myopia is largely derived from GWAS using
refractive error as a continuous variable (measured
as spherical equivalent) and self-reported history and
age of diagnosis of myopia.72,73 A multicohort meta-
analysis inclusive of individuals of both European and
Asian ancestry has discovered 167 loci associated with
refractive error, of which 138 loci were further repli-
cated in the UK Biobank cohort.74
Using these results, Tedja et al.74 created a compre-
hensive myopia PRS from 7307 variants, which
explained 7.8% of the refractive error variance of an
independent Dutch cohort. Individuals in the highest
PRS decile were at 40-fold greater risk of myopia
relative to the lowest decile.74 Furthermore, 24% of
people in the highest decile had high myopia (defined
by a spherical equivalent of –6 diopters or worse)
comparedwith 2% in the lowest decile.74 More recently,
Ghorbani Mojarrad et al.75 have used a multitrait
PRS combining GWAS of refractive error (spherical
equivalent), age of onset of spectacle wear, and years
spent in full-time education utilizing 7372 variants.
This multitrait analysis approach leverages the corre-
lated nature of these myopia-related traits despite the
overlapping GWAS samples. Individuals in the highest
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decile of this multitrait myopia PRS had 6.1-fold
(95% CI, 3.4–10.9) higher risk of developing high
myopia relative to the rest, a risk that could not
otherwise be inferred readily using demographic risk
factors. This is of particular clinical significance, as
high myopia is associated with complications that can
lead to irreversible vision impairment, most commonly
as a result of myopic macular degeneration.76 Finally,
combining the myopia PRS with information on the
number of myopic parents was more predictive (R2
= 7%) than either risk factor alone (R2 = 4.8% and
2.6% for number of myopic parents and PRS, respec-
tively), highlighting the added predictive ability of a
PRS-inclusive model.77
Despite these findings, myopia PRS have several
important limitations. Environmental risk factors, such
as near-work and outdoor time, have a high impact on
the etiology and progression of myopia in contrast to
common genetic loci with low effect-sizes.71,74 Further,
gene-environment interactions significantly affect the
clinical phenotype. For instance, Verhoeven et al.78
have reported lower education significantly masks the
genetic penetrance of developing myopia, possibly
related to lower time spent in near-work. Among
individuals with a high-risk PRS group, the odds of
developing a refractive error of at least –3 diopters
had a stepwise decline with decreasing education level
with an OR of 51, 22, and 7 among high, intermedi-
ate, and primary levels of education.78 This is in agree-
ment with several other studies of myopia-associated
variants showing differential and heterogeneous risks
of myopia development depending on age and educa-
tion levels.79–82
Screening and diagnosis of myopia is relatively easy
and affordable especially at a younger age, thereby
limiting the clinical utility of genetic testing in myopia
prediction. For instance, in a longitudinal study of
Chinese twin children, baseline refraction, age, and sex
was sufficient to predict risk of high myopia, and the
addition of a myopia PRS did not improve the model
(AUC 0.9569 vs. 0.9567 respectively; P = 0.7).83 A
key limitation of this study, however, is that the PRS
was not derived from an ancestrally matched popula-
tion, likely resulting in a lower signal-to-noise ratio and
incorrectly estimating the effect size of the included
variants. Despite this, PRS may be useful in identify-
ing individuals at high risk of developing pathological
myopia, in which irreversible vision loss is threatened
by progressive retinal atrophy, retinal detachment, or
choroidal neovascularization.74,76 This subgroup may
benefit from regular screening, counseling, and lifestyle
modification such increased time outdoors, which may
reduce progression.84
Future Directions, Advantages, and
Limitations of the PRS
Complex diseases are often diagnosed late in life
with a long period of preclinical or “asymptomatic”
disease. A key advantage of PRS risk stratification is
the ability to identify individuals before they develop
symptoms or irreversible pathology, and in some cases
also predict the risk of progression.15,38,57,68,74 Risk
stratification is best utilized in which early low-risk
intervention can alter the natural history of a disease
and improve quality of life, as has been reported
across a range of cardiovascular conditions.22,28,31,85
In addition, lifestyle modification (such as increas-
ing time outdoors for myopia, or smoking cessation
and dietary modification for AMD) and earlier or
more frequent screening strategies can be an effective
means of minimizing vision loss. POAG represents an
ideal case scenario for the clinical utility of PRS: it
is one of the most heritable common human diseases
without any strong environmental or lifestyle risk
factors35; has a prolonged asymptomatic disease phase
with irreversible vision loss54; has good outcomes
with early cost-effective and low-risk treatment that
can effectively halt vision loss86,87; there are highly
sensitive and noninvasive screening methods available
using optical coherence tomography88; and the avail-
ability of highly predictive PRS of disease risk and
phenotype.23,38
In health care systems with finite resources, target-
ing high-risk individuals with low-risk interventions,
and minimizing screening and interventions in low-
risk individuals, will improve the cost-benefit ratio of
these strategies and optimize resource allocation. There
will be a significant clinical and economic advantage
to target screening strategies to individuals at high risk
of developing a disease, while saving resources spent
on screening low-risk individuals, as has been shown
in the cancer screening setting.26,32,89 PRS can readily
be generated from public GWAS summary statistics,
and easily updated as newer and larger studies are
completed. Because the germline genome is fixed, once
generated genomic data can be queried simultaneously
at any time with any number of disease-specific PRS.
This is particularly beneficial in the fast-paced GWAS
literature, in which new risk variants are continuously
being reported and can be used to generate new and
improved PRS. However, additional research is needed
on how best to counsel patients on the risk of multi-
ple diseases and the ethical challenges this imposes. One
approach could be a tiered analysis during the lifetime
of the individual for different diseases, based on other
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relevant acquired risks (notably age) and interventions
and lifestyle modifications available at the time.
PRS are an increasingly effective and accurate
measure of the genetic component of disease risk,
which typically outperforms self-reported family
history.38,77,90,91 Although family history can capture
some of the genetic risk of a disease, it is often incom-
plete, imprecise, and strongly confounded by shared
environmental risk factors.90 Additionally, sporadic
cases with no known family history of a disease would
also benefit from genetic risk prediction. Nonethe-
less, PRS is not aimed at replacing clinical history
or screening programs as it is not a diagnostic test;
rather PRS can serve to improve risk stratification,
screening, and clinical decision-making. There is still a
need for prospective studies to test the clinical validity
and utility of PRS in routine clinical practice. The
design of such studies could involve stratification of
disease risk based on PRS, potentially followed by
randomization of high-risk patients into treatment
and control (standard of care) arms. The implemen-
tation of PRS in ophthalmic practice can be done at
the general practitioner level (primary prevention),
optometrists (screening), and specialists (phenotypic
and prognostic); however, further research is needed in
this area.
There are some challenges to the implementation
of PRS in clinical practice. To date, a disproportion-
ate majority of the large-scale GWAS—and thus the
PRS derived from them—were performed in popula-
tions of European ancestry.92 There is evidence that
there is a disparity in LD patterns and risk allele
frequencies between African and non-African popula-
tions, which impairs the translation of a majority of
the current PRSs to African populations.93 There-
fore the predictive power of a PRS derived from a
majority European ancestry cohort can be lower when
applied to other ethnicities.92 For example, although
a glaucoma PRS derived from a cohort of European
ancestry was predictive of glaucoma risk in South
Asian individuals, it had a slightly better predictive
power in an independent cohort of European ances-
try (AUC of 0.76, 95% CI, 0.73–0.79 vs. AUC of 0.79,
95% CI, 0.75–0.84, respectively).38 Validation studies
and mixed-ancestry GWAS are essential for the effec-
tive translation of PRS to clinical practice. Further-
more, there is little consensus on the methodology to
calculate PRS, or the analysis methods used to report
findings. For instance, reports of top to bottom decile
comparisons exaggerate the performance of PRS for
clinical settings, in which a relative risk comparison to
the general population risk is more clinically relevant.
This limits ease of comparison, replication, and valida-
tion of the published scores. An evidence-based and
consistent analysis approach, as well as detailed report-
ing of the variants and methods used to generate each
score, will address these issues. This is currently being
addressed by the active development of The Polygenic
Score Catalog, an online repository of published PRS
with full annotation of variants, weights, and reported
performance metrics.94 Finally, PRS research should
aim to address clinical questions on the utility of the
score in a disease-specific manner, rather than focusing
solely on statistical prediction accuracies. For instance,
a younger age of disease diagnosis (and thus a higher
morbidity) or risk of disease progression or vision
loss in the affected or contralateral eye would be more
relevant as a translational clinical outcome. Clinicians
and genetic counselors are then needed to communi-
cate genetic risk to patients in a personalized manner
with actionable monitoring frequencies and lifestyle or
pharmacologic intervention suggestions. This imple-
mentation, however, will require additional clinician
education, updated guidelines, and end-user engage-
ment.
For the adaptation of PRS into clinical practice
to be successful, comprehensive understanding of
population attitudes toward such testing is critical.
It is known that in general, genetic susceptibility
testing is well received and supported. Preliminary
studies have shown positive interest in genetic testing
for Mendelian variants for glaucoma, particularly
when applied in appropriate circumstances, such as
in families with a strong family history.95 However,
little is known about factors associated with uptake
of PRS. A pilot study on using genetic testing to
guide behavioral modification for AMD risk reduc-
tion reported that about one-third of the partici-
pants implemented specific personal protective behav-
iors following optometrist-guided genetic counseling.96
Another pilot study assessing uptake of polygenic risk
information for breast cancer in women identified that
a family history of disease, higher levels of education,
and perceived benefit of testing were factors associ-
ated with improved uptake.97 However, more research
is needed to better understand barriers to implementa-
tion and factors, which may influence patient decision-
making.
Conclusions
PRS is a powerful tool in disease risk stratification,
and prognostication in common complex diseases. The
ideal clinical use scenario is in conditions in which
early intervention will alter the natural history of
the disease and reduce morbidity or mortality. We
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have summarized the existing literature supporting
the utility of PRS risk stratification in three major
ophthalmic conditions: POAG, AMD, and myopia.
In these heritable diseases, PRS is highly informative
of disease risk and may offer additional information
about disease progression. A major advantage of PRS
is the ability to calculate the risk of multiple diseases
and phenotypes at any point in life using data from a
single genotyping array. Importantly, it is not intended
to be a diagnostic test, but rather a risk stratifying tool.
Future research should focus on the clinical implemen-
tation of the PRS to inform personalized and targeted
clinical decision-making.
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